444 related articles for article (PubMed ID: 38541800)
1. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.
Barachini S; Buda G; Petrini I
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541800
[TBL] [Abstract][Full Text] [Related]
2. Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.
Vakilpour A; Lefebvre B; Lai C; Scherrer-Crosbie M
Blood Rev; 2024 Mar; 64():101166. PubMed ID: 38182490
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.
Lanza O; Ferrera A; Reale S; Solfanelli G; Petrungaro M; Tini Melato G; Volpe M; Battistoni A
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736347
[TBL] [Abstract][Full Text] [Related]
5. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
Asnani A; Moslehi JJ; Adhikari BB; Baik AH; Beyer AM; de Boer RA; Ghigo A; Grumbach IM; Jain S; Zhu H;
Circ Res; 2021 Jun; 129(1):e21-e34. PubMed ID: 33934611
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology: Understanding the different mechanisms of cardiovascular toxicity.
Toste JC
Rev Port Cardiol; 2022 Jul; 41(7):587-597. PubMed ID: 36065779
[TBL] [Abstract][Full Text] [Related]
9. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
11. Role of oxidative stress in cardiotoxicity of antineoplastic drugs.
Zhang X; Zhu Y; Dong S; Zhang A; Lu Y; Li Y; Lv S; Zhang J
Life Sci; 2019 Sep; 232():116526. PubMed ID: 31170418
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Complications in the Adult Bone Marrow Transplant Patient.
Tuzovic M; Mead M; Young PA; Schiller G; Yang EH
Curr Oncol Rep; 2019 Mar; 21(3):28. PubMed ID: 30826891
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline chemotherapy, vascular dysfunction and cognitive impairment: burgeoning topics and future directions.
Maurer GS; Clayton ZS
Future Cardiol; 2023 Sep; 19(11):547-566. PubMed ID: 36354315
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
Yeh ETH; Ewer MS; Moslehi J; Dlugosz-Danecka M; Banchs J; Chang HM; Minotti G
Semin Oncol; 2019 Dec; 46(6):397-402. PubMed ID: 31753424
[TBL] [Abstract][Full Text] [Related]
16. Cell death regulation in myocardial toxicity induced by antineoplastic drugs.
Yu X; Yang Y; Chen T; Wang Y; Guo T; Liu Y; Li H; Yang L
Front Cell Dev Biol; 2023; 11():1075917. PubMed ID: 36824370
[TBL] [Abstract][Full Text] [Related]
17. Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.
Yang X; Li G; Yang T; Guan M; An N; Yang F; Dai Q; Zhong C; Luo C; Gao Y; Das S; Xing Y; Shang H
Oxid Med Cell Longev; 2020; 2020():4894625. PubMed ID: 33110473
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Sep; 47(9):779-785. PubMed ID: 28531278
[TBL] [Abstract][Full Text] [Related]
19. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
20. Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.
Dillenburg RF; Nathan P; Mertens L
Eur J Pediatr; 2013 Sep; 172(9):1149-60. PubMed ID: 23361962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
